| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.002 | 0.9 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.0045 | 1 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.0044 | 1 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.0028 | 1 |